Home The association of paraoxonase I gene polymorphisms Q192R (rs662) and L55M (rs854560) and its activity with metabolic syndrome components in fars ethnic group
Article
Licensed
Unlicensed Requires Authentication

The association of paraoxonase I gene polymorphisms Q192R (rs662) and L55M (rs854560) and its activity with metabolic syndrome components in fars ethnic group

  • Abdoljalal Marjani EMAIL logo , Nahid Poursharifi , Mohammad Mostakhdem Hashemi , Atefe Sajedi and Mahin Tatari
Published/Copyright: February 17, 2023
Become an author with De Gruyter Brill
Submit Manuscript Author Information
Hormone Molecular Biology and Clinical Investigation
From the journal Hormone Molecular Biology and Clinical Investigation Volume 44 Issue 3

Abstract

Objectives

Metabolic syndrome (MetS) may cause premature development of some diseases. PON1 genes may be involved in the pathogenesis of MetS. The aim of study was to evaluate the association between Q192R and L55M gene polymorphisms and its enzyme activity with the MetS components in subjects with and without MetS.

Methods

Polymerase Chain Reaction and Restriction Fragment Length Polymorphism analysis were performed to determine polymorphisms of the paraoxonase1 gene in subjects with and without metabolic syndrome. Biochemical parameters were measured by spectrophotometer.

Results

The MM, LM, and LL genotype frequencies of the PON1 L55M polymorphism were 10.5, 43.4, and 46.1%, and 22.4, 46.6, and 31% and; the QQ, QR, and RR genotype frequencies of the PON1 Q192R polymorphism were 55.4, 38.6 and 6%; and 56.5, 34.8 and 8.7% in subjects with and without MetS, respectively. The L and M allele frequencies were 68 and 53%; and 32 and 47% for PON1 L55M in subjects with and without MetS, respectively. The Q and R allele frequencies for PON1 Q192R were 74 and 26% in both groups. There were significant differences in HDL-cholesterol level and PON1 activity in the genotypes QQ, QR, and RR of the PON1 Q192R polymorphism in subjects with MetS.

Conclusions

The PON1 Q192R genotypes had only effected on PON1 activity and HDL-cholesterol level in subjects with MetS. Different genotypes of the PON1 Q192R seem to be important candidates to make the subjects susceptible to MetS in the Fars ethnic group.

Keywords: activity; fars ethnic; metabolic syndrome; paraoxonase 1; polymorphism
Corresponding author: Abdoljalal Marjani, Metabolic Disorders Research Center, Department of Biochemistry and Biophysics, Faculty of Medicine, Golestan University of Medical Sciences, Golestan, Gorgan, Iran, Phone & Fax: +98(173)4421651 & 4440225, Zip code: 4934174515, E-mail:

Funding source: Golestan University of Medical Sciences

Award Identifier / Grant number: Unassigned

Acknowledgments

The authors would like to be thankful for financial support of Research Deputy of Golestan University of Medical Sciences.

  1. Research funding: This work has been supported by Research Deputy of Golestan University of Medical Science.

  2. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  3. Competing interests: Authors state no conflict of interest.

  4. Informed consent: Informed consent was obtained from all individuals included in this study.

  5. Ethical approval: The Golestan University of Medical Sciences Ethics Committee (Ethic number: IR.GOUMS.REC.1397.229) was approved this study, according to the Declaration of Helsinki and Good Clinical Practice guidelines.

References

1. Okada, K, Hibi, K, Gohbara, M, Kataoka, S, Takano, K, Akiyama, E, et al.. Association between blood glucose variability and coronary plaque instability in patients with acute coronary syndromes. Cardiovasc Diabetol 2015;14:111. https://doi.org/10.1186/s12933-015-0275-3.Search in Google Scholar PubMed PubMed Central

2. Marjani, A, Shahini, N, Atabay, OA, Tabari, RG. Prevalence of metabolic syndrome among sistanee ethnic women. Adv Stud Biol 2012;4:363–72.Search in Google Scholar

3. Marjani, A, Hezarkhani, S, Shahini, N. Prevalence of metabolic syndrome among fars ethnic women in north east of Iran. World J Med Sci 2012;7:17–22.Search in Google Scholar

4. Shahini, N, Shahini, I, Marjani, A. Prevalence of metabolic syndrome in Turkmen ethnic groups in gorgan. J Clin Diagn Res 2013;7:1849–51. https://doi.org/10.7860/JCDR/2013/6035.3331.Search in Google Scholar PubMed PubMed Central

5. Marjani, A, Hezarkhani, S, Shahini, N. Prevalence of metabolic syndrome among fars ethnic women in north east of Iran. World J Med Sci 2012;7:17–22.Search in Google Scholar

6. Kolovou, GD, Anagnostopoulou, KK, Salpea, KD, Mikhailidis, DP. The prevalence of metabolic syndrome in various populations. Am J Med Sci 2007;333:362–71. https://doi.org/10.1097/maj.0b013e318065c3a1.Search in Google Scholar PubMed

7. Gupta, A, Gupta, R, Sarna, M, Rastogi, S, Gupta, VP, Kothari, K. Prevalence of diabetes, impaired fasting glucose and insulin resistance syndrome in an urban Indian population. Diabetes Res Clin Pract 2003;61:69–76. https://doi.org/10.1016/s0168-8227(03)00085-8.Search in Google Scholar PubMed

8. Balkau, B, Vernay, M, Mhamdi, L, Novak, M, Aronde, D, Tichet, J, et al.. The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. The French D.E.S.I.R. study. Diabetes Metab 2003;29:526–32. https://doi.org/10.1016/s1262-3636(07)70067-8.Search in Google Scholar PubMed

9. Ramachandran, A, Snehalatha, C, Satyavani, K, Sivasankari, S, Vijay, V. Metabolic syndrome in urban Asian Indian adults-a population study using modified ATP III criteria. Diabetes Res Clin Pract 2003;60:199–204. https://doi.org/10.1016/s0168-8227(03)00060-3.Search in Google Scholar PubMed

10. For, ES, Giles, WH, Dietz, WH. Prevalence of the metabolic syndrome among US adults: findings from the Third national health and nutrition examination survey. J Am Med Assoc 2002;287:356–9. https://doi.org/10.1001/jama.287.3.356.Search in Google Scholar PubMed

11. Cameron, AJ, Shaw, JE, Zimmet, PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin N Am 2004;33:351–75. https://doi.org/10.1016/j.ecl.2004.03.005.Search in Google Scholar PubMed

12. The Research Group ATS-RF2 of the Italian National Research Council. Distribution of some risk factors for atherosclerosis in nine Italian population samples. Am J Epidemiol 1981;113:338–46. https://doi.org/10.1093/oxfordjournals.aje.a113102.Search in Google Scholar PubMed

13. Meigs, JB. Invited commentary: insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am J Epidemiol 2000;152:908–11. https://doi.org/10.1093/aje/152.10.908.Search in Google Scholar PubMed

14. Shekhanawar, M, Shekhanawar, SM, Krisnaswamy, D, Indumati, V, Satishkumar, D, Vijay, V, et al.. The role of ‘paraoxonase-1 activity’ as an antioxidant in coronary artery diseases. J Clin Diagn Res 2013;7:1284–7. https://doi.org/10.7860/JCDR/2013/5144.3118.Search in Google Scholar PubMed PubMed Central

15. Primo-Parmo, SL, Sorenson, RC, Teiber, J, Du, BNL. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996;33:498–507. https://doi.org/10.1006/geno.1996.0225.Search in Google Scholar PubMed

16. Rajkovic, MG, Rumora, L, Barisic, K. The paraoxonase 1, 2 and 3 in humans. Biochem Med 2011;21:122–30. https://doi.org/10.11613/bm.2011.020.Search in Google Scholar PubMed

17. Furlong, CE, Marsillach, J, Jarvik, GP, Costa, LG. Paraoxonases-1, -2 and -3: what are their functions? Chem Biol Interact 2016;259:51–62. https://doi.org/10.1016/j.cbi.2016.05.036.Search in Google Scholar PubMed PubMed Central

18. Mazur, A. An enzyme in animal tissues capable of hydrolysing the phosphorus-fluorine bond of alkyl fluorophosphates. J Biol Chem 1946;164:271–89. https://doi.org/10.1016/s0021-9258(18)43068-2.Search in Google Scholar

19. Sorenson, RC, Primo-Parmo, SL, Camper, SA, La Du, BN. The genetic mapping and gene structure of mouse paraoxonase/arylesterase. Genomics 1995;30:431–8. https://doi.org/10.1006/geno.1995.1261.Search in Google Scholar PubMed

20. Humbert, R, Adler, DA, Disteche, CM, Hassett, C, Omiecinski, CJ, Furlong, CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993;3:73–6. https://doi.org/10.1038/ng0193-73.Search in Google Scholar PubMed

21. Ferretti, G, Bacchetti, T. Effect of dietary lipids on paraoxonase-1 activity and gene expression. Nutr Metabol Cardiovasc Dis 2012;22:88–94. https://doi.org/10.1016/j.numecd.2011.08.011.Search in Google Scholar PubMed

22. Aviram, M, Rosenblat, M, Bisgaier, CL, Newton, RS, Primo-Parmo, SL, La Du, BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998;101:1581–90. https://doi.org/10.1172/jci1649.Search in Google Scholar

23. Yildiz, A, Gür, M, Yilmaz, R, Demirbag, R, Polat, M, Selek, S, et al.. Association of paraoxonase activity and coronary blood flow. Atherosclerosis 2008;197:257–63. https://doi.org/10.1016/j.atherosclerosis.2007.04.004.Search in Google Scholar PubMed

24. Tang, WHW, Hartiala, J, Fan, Y, Wu, Y, Stewart, AF, Erdmann, J, et al.. Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk. Arterioscler Thromb Vasc Biol 2012;32:2803–12. https://doi.org/10.1161/atvbaha.112.253930.Search in Google Scholar

25. Chen, F, Ding, J, Chen, Q, Zhuang, X, Feng, Z, Xu, L. Low paraoxonase 1 arylesterase activity and high von Willebrand factor levels are associated with severe coronary atherosclerosis in patients with non-diabetic stable coronary artery disease. Med Sci Mon Int Med J Exp Clin Res 2014;20:2421–9. https://doi.org/10.12659/msm.890911.Search in Google Scholar PubMed PubMed Central

26. Wysocka, A, Cybulski, M, Wysokiński, AP, Berbeć, H, Stążka, J, Zapolski, T. Paraoxonase 1 activity, polymorphism and atherosclerosis risk factors in patients undergoing coronary artery surgery. J Clin Med 2019;8:441. https://doi.org/10.3390/jcm8040441.Search in Google Scholar PubMed PubMed Central

27. AnandBabu, K, Bharathidevi, S, Sripriya, S, Sen, P, Prakash, VJ, Bindu, A, et al.. Serum paraoxonase activity in relation to lipid profile in age-related macular degeneration patients. Exp Eye Res 2016;152:100–12. https://doi.org/10.1016/j.exer.2016.09.009.Search in Google Scholar PubMed

28. Seo, D, Goldschmidt-Clermont, P. The paraoxonase gene family and atherosclerosis. Curr Atherosclerosis Rep 2009;11:182–7. https://doi.org/10.1007/s11883-009-0029-3.Search in Google Scholar PubMed

29. Martinelli, N, Micaglio, R, Consoli, L, Guarini, P, Grison, E, Pizzolo, F, et al.. Low levels of serum paraoxonase activities are characteristic of metabolic syndrome and may influence the metabolic-syndrome-related the metabolic-syndrome-related risk of coronary artery disease. Exp Diabetes Res 2012;2012:231502.10.1155/2012/231502Search in Google Scholar PubMed PubMed Central

30. Expert Panel on Detection and Evaluation of High Blood Cholesterol in Adults. Executive summary of the third report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285:2486–97, https://doi.org/10.1001/jama.285.19.2486.Search in Google Scholar PubMed

31. Chang, M. Bertilsson L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995;5:358–63. https://doi.org/10.1097/00008571-199512000-00004.Search in Google Scholar PubMed

32. Winham, SJ, de Andrade, M, Miller, VM. Genetics of cardiovascular disease: importance of sex and ethnicity. Atherosclerosis 2015;241:219–28. https://doi.org/10.1016/j.atherosclerosis.2015.03.021.Search in Google Scholar PubMed PubMed Central

33. Ehret, GB, Munroe, PB, Rice, KM, Bochud, M, Johnson, AD, Chasman, DI, et al.. CHARGEHF consortium. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 2011;478:103–9. https://doi.org/10.1038/nature10405.Search in Google Scholar PubMed PubMed Central

34. Litvinov, D, Mahini, H, Garelnabi, M. Antioxidant and anti-inflammatory role of paraoxonase 1: implication in arteriosclerosis diseases. N Am J Med Sci 2012;4:523–32. https://doi.org/10.4103/1947-2714.103310.Search in Google Scholar PubMed PubMed Central

35. Kowalska, K, Socha, E, Milnerowicz, H. Review: the role of paraoxonase in cardiovascular diseases. Ann Clin Lab Sci 2015;45:226–33.Search in Google Scholar

36. Mackness, MI, Arrol, S, Durrington, PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991;286:152–4. https://doi.org/10.1016/0014-5793(91)80962-3.Search in Google Scholar PubMed

37. Koda, Y, Tachida, H, Soejima, M, Takenaka, O, Kimura, H. Population differences inDNA sequence variation and linkage disequilibrium at the PON1gene. Ann Hum Genet 2004;68:110–9.24. https://doi.org/10.1046/j.1529-8817.2003.00077.x.Search in Google Scholar PubMed

38. Ciumarean, L, Dronca, E, Vesa, SC, Sampelean, D, Buzoianu, AD, Achimas-Cadariu, A. Paraoxonase 1 genotype–phenotype correlation in patients with metabolic syndrome. Rom J Morphol Embryol 2015;56:387–92.Search in Google Scholar

39. Senti, M, Tomas, M, Fito, M, Weinbrenner, T, Covas, MI, Sala, J, et al.. Antioxidant paraoxonase 1 activity in the metabolic syndrome. J Clin Endocrinol Metab 2003;88:5422–6. https://doi.org/10.1210/jc.2003-030648.Search in Google Scholar PubMed

40. Tabur, S, Torun, AN, Sabuncu, T, Turan, MN, Celik, H, Ocak, AR, et al.. Non-diabetic metabolic syndrome and obesity do not affect serum paraoxonase and arylesterase activities but do affect oxidative stress and inflammation. Eur J Endocrinol 2011;162:535–41. https://doi.org/10.1530/eje-09-0732.Search in Google Scholar PubMed

41. Saha, N, Roy, AC, Teo, SH, Tay, JSH, Ratnam, SS. Influence of serum paraoxonase polymorphism on serum lipids and lipoproteins. Clin Genet 1991;40:277–82. https://doi.org/10.1111/j.1399-0004.1991.tb03096.x.Search in Google Scholar PubMed

42. Abello, D, Sancho, E, Camps, J, Joven, J. Exploring the role of paraoxonases in the pathogenesis of coronary artery disease: a systematic review. Int J Mol Sci 2014;15:20997–1010. https://doi.org/10.3390/ijms151120997.Search in Google Scholar PubMed PubMed Central

43. Fathi Dizaji, B, Rivandi, M, Javandoost, A, Saberi Karimian, M, Raei, A, Sahebkar, AH, et al.. Association of genetic polymorphisms of PON1 and CETP with the presence of metabolic syndrome; the effects of genotypes on their serum activity and concentrations. Egypt J Med Hum Genet 2018;19:43–8. https://doi.org/10.1016/j.ejmhg.2017.12.001.Search in Google Scholar

44. Kordi-Tamandani, DM, Hashemi, M, Sharifi, N, Kaykhaei, MA, Torkamanzehi, A. Association between paraoxonase-1 gene polymorphisms and risk of metabolic syndrome. Mol Biol Rep 2012;39:937–43. https://doi.org/10.1007/s11033-011-0819-x.Search in Google Scholar PubMed

45. Shin, BS. Paraoxonase gene polymorphism in south-western Korean population. J Kor Med Sci 2009;24:561–6. https://doi.org/10.3346/jkms.2009.24.4.561.Search in Google Scholar PubMed PubMed Central

46. Yamada, Y, Ando, F, Niino, N, Miki, T, Shimokata, H. Association of polymorphisms of paraoxonase 1 and 2 genes, alone or in combination, with bone mineral density in community-dwelling Japanese. J Hum Genet 2003;48:469–75. https://doi.org/10.1007/s10038-003-0063-x.Search in Google Scholar PubMed

47. Li, WF, Pan, MH, Chung, MC, Ho, CK, Chuang, HY. Lead exposure is associated with decreased serum paraoxonase 1 (PON1) activity and genotypes. Environ Health Perspect 2006;114:1233–6. https://doi.org/10.1289/ehp.9163.Search in Google Scholar PubMed PubMed Central

48. Phuntuwate, W, Suthisisang, C, Koanantakul, B, Mackness, MI, Mackness, B. Paraoxonase 1 status in the Thai population. J Hum Genet 2005;50:293–300. https://doi.org/10.1007/s10038-005-0255-7.Search in Google Scholar PubMed

49. Watzinger, N, Schmidt, H, Schumacher, M, Schmidt, R, Eber, B, Fruhwald, FM, et al.. Human paraoxonase 1 gene polymorphisms and the risk of coronary heart disease: a community- based study. Cardiology 2002;98:116–22. https://doi.org/10.1159/000066321.Search in Google Scholar PubMed

50. Hasselwander, O, Savage, DA, McMaster, D, Loughrey, CM, McNamee, PT, Middleton, D, et al.. Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients. Kidney Int 1999;56:289–98. https://doi.org/10.1046/j.1523-1755.1999.00521.x.Search in Google Scholar PubMed

51. Agachan, B, Yilmaz, H, Ergen, HA, Karaali, ZE, Isbir, T. Paraoxonase (PON1) 55 and 192 polymorphism and its effects to oxidant-antioxidant system in Turkish patients with type 2 diabetes mellitus. Physiol Res 2005;54:287–93. https://doi.org/10.33549/physiolres.930530.Search in Google Scholar

52. Garin, MC, Kalix, B, Morabia, A, James, RW. Small, dense lipoprotein particles and reduced paraoxonase-1 in patients with the metabolic syndrome. J Clin Endocrinol Metab 2005;90:2264–9. https://doi.org/10.1210/jc.2004-1295.Search in Google Scholar PubMed

53. Ranade, K, Kirchgessner, TG, Iakoubova, OA, Devlin, JJ, DelMonte, T, Vishnupad, P, et al.. Evaluation of the paraoxonases as candidate genes for stroke: gln192Arg polymorphism in the paraoxonase 1 gene is associated with increased risk of stroke. Stroke 2005;36:2346–50. https://doi.org/10.1161/01.str.0000185703.88944.7d.Search in Google Scholar

54. McKeown-Eyssen, G, Baines, C, Cole, DE, Riley, N, Tyndale, RF, Marshall, L, et al.. Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR. Int J Epidemiol 2004;33:971–8. https://doi.org/10.1093/ije/dyh251.Search in Google Scholar PubMed

55. Gardemann, A, Philipp, M, Hess, K, Katz, N, Tillmanns, H, Haberbosch, W. The paraoxonase Leu-Met54 and Gln-Arg191 gene polymorphisms are not associated with the risk of coronary heart disease. Atherosclerosis 2000;152:421–31. https://doi.org/10.1016/s0021-9150(99)00489-x.Search in Google Scholar PubMed

56. Slowik, A, Wloch, D, Szermer, P, Wolkow, P, Malecki, M, Pera, J, et al.. Paraoxonase 2 gene C311S polymorphism is associated with a risk of large vessel disease stroke in a Polish population. Cerebrovasc Dis 2007;23:395–400. https://doi.org/10.1159/000101462.Search in Google Scholar PubMed

57. Mackness, B, Durrington, PN, Mackness, MI. The paraoxonase gene family and coronary heart disease. Curr Opin Lipidol 2002;13:357–62. https://doi.org/10.1097/00041433-200208000-00002.Search in Google Scholar PubMed

58. Mackness, B, Davies, GK, Turkie, W, Lee, E, Roberts, DH, Hill, E, et al.. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 2001;21:1451–7. https://doi.org/10.1161/hq0901.094247.Search in Google Scholar PubMed

59. She, ZG, Chen, HZ, Yan, Y, Li, H, Liu, DP. The human paraoxonase gene cluster as a target in the treatment of atherosclerosis. Antioxidants Redox Signal 2012;16:597–632. https://doi.org/10.1089/ars.2010.3774.Search in Google Scholar PubMed PubMed Central

60. Khersonsky, O, Tawfik, DS. Structure-reactivity studies of serum paraoxonase PON1 suggest that its true native activity is lactonase. Biochemistry 2005;44:6371–82. https://doi.org/10.1021/bi047440d.Search in Google Scholar PubMed

61. Dansette, PM, Rosi, J, Bertho, G, Mansuy, D. Paraoxonase-1 and clopidogrel efficacy. Nat Med 2011;17:1040. https://doi.org/10.1038/nm.2436.Search in Google Scholar PubMed

62. Hegele, RA, Brunt, JH, Connelly, PW. A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. Arterioscler Thromb Vasc Biol 1995;15:89–95. https://doi.org/10.1161/01.atv.15.1.89.Search in Google Scholar PubMed

Received: 2022-06-26
Accepted: 2023-01-22
Published Online: 2023-02-17

© 2023 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Original Articles
  3. The effect of encomir-93 mimic transfection on the expression of miR-93 and PSA and androgen receptor in prostate cancer LNcap cell line
  4. Association of S19W polymorphism in APOA5 gene and serum lipid levels in patients with type 2 diabetic nephropathy
  5. Examining the effect of Helicobacter pylori cagPAI variety on gene expression pattern related to gastric cancer
  6. Plasma IL-6, TREM1, uPAR, and IL6/IL8 biomarkers increment further witnessing the chronic inflammation in type 2 diabetes
  7. The effect of miR-372-5p regulation on CDX1 and CDX2 in the gastric cancer cell line
  8. Point-of-care salivary oxidative and renal functional markers to assess kidney function in reperfusion-induced acute kidney injury in male rats
  9. The differential role of resistin on invasive liver cancer cells
  10. The association of paraoxonase I gene polymorphisms Q192R (rs662) and L55M (rs854560) and its activity with metabolic syndrome components in fars ethnic group
  11. Metabolic syndrome – cardiac structure and functional analysis by echocardiography; a cross sectional comparative study
  12. Investigation of the relationship between betatrophin and certain key enzymes involved in carbohydrate and lipid metabolism in insulin-resistant mice
  13. Intermittent vs. continuous swimming training on adipokines and pro-inflammatory cytokines in metabolic syndrome experimental model
  14. Effect of four-week home-based exercise program on immune response, fat and muscle mass in subjects recovered from COVID-19
  15. Review Article
  16. Analytical and therapeutic profiles of DNA methylation alterations in cancer; an overview of changes in chromatin arrangement and alterations in histone surfaces
https://doi.org/10.1515/hmbci-2022-0064
Keywords for this article
activity; fars ethnic; metabolic syndrome; paraoxonase 1; polymorphism

Articles in the same Issue

  1. Frontmatter
  2. Original Articles
  3. The effect of encomir-93 mimic transfection on the expression of miR-93 and PSA and androgen receptor in prostate cancer LNcap cell line
  4. Association of S19W polymorphism in APOA5 gene and serum lipid levels in patients with type 2 diabetic nephropathy
  5. Examining the effect of Helicobacter pylori cagPAI variety on gene expression pattern related to gastric cancer
  6. Plasma IL-6, TREM1, uPAR, and IL6/IL8 biomarkers increment further witnessing the chronic inflammation in type 2 diabetes
  7. The effect of miR-372-5p regulation on CDX1 and CDX2 in the gastric cancer cell line
  8. Point-of-care salivary oxidative and renal functional markers to assess kidney function in reperfusion-induced acute kidney injury in male rats
  9. The differential role of resistin on invasive liver cancer cells
  10. The association of paraoxonase I gene polymorphisms Q192R (rs662) and L55M (rs854560) and its activity with metabolic syndrome components in fars ethnic group
  11. Metabolic syndrome – cardiac structure and functional analysis by echocardiography; a cross sectional comparative study
  12. Investigation of the relationship between betatrophin and certain key enzymes involved in carbohydrate and lipid metabolism in insulin-resistant mice
  13. Intermittent vs. continuous swimming training on adipokines and pro-inflammatory cytokines in metabolic syndrome experimental model
  14. Effect of four-week home-based exercise program on immune response, fat and muscle mass in subjects recovered from COVID-19
  15. Review Article
  16. Analytical and therapeutic profiles of DNA methylation alterations in cancer; an overview of changes in chromatin arrangement and alterations in histone surfaces
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 24.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/hmbci-2022-0064/html
Scroll to top button